OTTAWA, ON, June 9, 2021 / PRNewswire / – Replica Analytics today announced the creation of a Advisory Board and its first three members.
The three new members have extensive experience in health research, data analysis, data sharing and bringing health technology innovations to market.
Anil Sethi is the CEO of Citizen, a platform that helps patients turn paper files into predictable data that can then be matched against clinical trials, and enables clinical research in general. He has founded seven health technology companies in his career to date.
Janice Branson is Global Head of Advanced Methodology and Data Science at Novartis, who leads data science and statistics teams worldwide in all therapeutic areas, with a special focus on immunology, hepatology and dermatology, respiration and metabolism.
Jason Colquitt is CEO of Across Healthcare, the Matrix software Platform for the rapid provision of rare disease registries.
“We have put together a very strong team of consultants who will help the company with the market launch of our replica synthesis software to cope with the next phases of innovation and growth. The business benefits of our synthetic data generation technology are quite significant, and we have gathered several compelling case studies and reference customers. I look forward to working with our new advisory board members to bring Replica Analytics through the next milestones. “
Khaled El Emam, the CEO of Replica Analytics
“I am excited to join the Replica Analytics Advisory Board. The company’s technology has the potential to transform the way we access and share data and the way we conduct clinical research. and I find him very thoughtful. “
Anil Sethi, Replica Analytics Advisory Board and CEO of Ciitizen
About replica analyzes Replicate analysis develops unique technologies for the generation of data protection-protecting synthetic data that retain the statistical properties of real data. Replica Synthesis software offers a full suite of synthetic data generation and analysis capabilities that can solve several major challenges for the life science industry and health research in general. Synthetic data enables rapid innovation by accelerating the development of AI models and clinical studies through data simulation.
SOURCE Replica Analysis